CD19 and systemic lupus erythematosus: Following the success of SLE, clinical research has extended the use of anti-CD19 CAR T-cell therapy to other autoimmune conditions, such as systemic sclerosis (101–103), refractory immune-mediated necrotizing myopathy (103), refractory anti-synthetase syndrome (104, 105), and myasthenia gravis (96).